These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16515873)

  • 1. Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: further evidence that CLN3P has anti-apoptotic properties.
    Narayan SB; Rakheja D; Pastor JV; Rosenblatt K; Greene SR; Yang J; Wolf BA; Bennett MJ
    Mol Genet Metab; 2006 Jun; 88(2):178-83. PubMed ID: 16515873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.
    Rusyn E; Mousallem T; Persaud-Sawin DA; Miller S; Boustany RM
    Pediatr Res; 2008 Jun; 63(6):625-31. PubMed ID: 18317235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease.
    Narayan SB; Pastor JV; Mitchison HM; Bennett MJ
    Brain; 2004 Aug; 127(Pt 8):1748-54. PubMed ID: 15240430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update.
    Rakheja D; Narayan SB; Bennett MJ
    Curr Mol Med; 2007 Sep; 7(6):603-8. PubMed ID: 17896996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amlodipine prevents apoptotic cell death by correction of elevated intracellular calcium in a primary neuronal model of Batten disease (CLN3 disease).
    Warnock A; Tan L; Li C; An Haack K; Narayan SB; Bennett MJ
    Biochem Biophys Res Commun; 2013 Jul; 436(4):645-9. PubMed ID: 23769828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
    Chan CH; Ramirez-Montealegre D; Pearce DA
    Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CLN3 gene is a novel molecular target for cancer drug discovery.
    Rylova SN; Amalfitano A; Persaud-Sawin DA; Guo WX; Chang J; Jansen PJ; Proia AD; Boustany RM
    Cancer Res; 2002 Feb; 62(3):801-8. PubMed ID: 11830536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for calcium channel modulators in CLN3 siRNA knock down SH-SY5Y neuroblastoma cells reveals a significant decrease of intracellular calcium levels by selected L-type calcium channel blockers.
    An Haack K; Narayan SB; Li H; Warnock A; Tan L; Bennett MJ
    Biochim Biophys Acta; 2011 Feb; 1810(2):186-91. PubMed ID: 20933060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
    Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
    Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Batten disease with the yeast Saccharomyces cerevisiae.
    Pearce DA; Sherman F
    Mol Genet Metab; 1999 Apr; 66(4):314-9. PubMed ID: 10191120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective lysosomal arginine transport in juvenile Batten disease.
    Ramirez-Montealegre D; Pearce DA
    Hum Mol Genet; 2005 Dec; 14(23):3759-73. PubMed ID: 16251196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drafting the CLN3 protein interactome in SH-SY5Y human neuroblastoma cells: a label-free quantitative proteomics approach.
    Scifo E; Szwajda A; Dębski J; Uusi-Rauva K; Kesti T; Dadlez M; Gingras AC; Tyynelä J; Baumann MH; Jalanko A; Lalowski M
    J Proteome Res; 2013 May; 12(5):2101-15. PubMed ID: 23464991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CLN3P, the Batten disease protein, localizes to membrane lipid rafts (detergent-resistant membranes).
    Rakheja D; Narayan SB; Pastor JV; Bennett MJ
    Biochem Biophys Res Commun; 2004 May; 317(4):988-91. PubMed ID: 15094366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of pH regulation by Btn1p, the yeast homolog of human Cln3p.
    Pearce DA; Nosel SA; Sherman F
    Mol Genet Metab; 1999 Apr; 66(4):320-3. PubMed ID: 10191121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Batten disease gene CLN3 confers resistance to endoplasmic reticulum stress induced by tunicamycin.
    Wu D; Liu J; Wu B; Tu B; Zhu W; Luo J
    Biochem Biophys Res Commun; 2014 Apr; 447(1):115-20. PubMed ID: 24699413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic analysis of neuronal ceroid lipofuscinosis.
    Mole SE; Gardiner M
    Int J Neurol; 1991-1992; 25-26():52-9. PubMed ID: 11980063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A knock-in reporter mouse model for Batten disease reveals predominant expression of Cln3 in visual, limbic and subcortical motor structures.
    Ding SL; Tecedor L; Stein CS; Davidson BL
    Neurobiol Dis; 2011 Feb; 41(2):237-48. PubMed ID: 20875858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin.
    Chang JW; Choi H; Kim HJ; Jo DG; Jeon YJ; Noh JY; Park WJ; Jung YK
    Hum Mol Genet; 2007 Feb; 16(3):317-26. PubMed ID: 17189291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving towards therapies for juvenile Batten disease?
    Cooper JD
    Exp Neurol; 2008 Jun; 211(2):329-31. PubMed ID: 18400221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
    Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
    Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.